Genetic Characterization of Myoid Hamartoma of the Breast
Conclusion: Myoid hamartoma of the breast may be pathogenetically related to benign connective tissue tumors with HMGA2 rearrangements, such as pulmonary hamartomas, lipomas, myolipomas, and leiomyomas.
Condition: Malignant Neoplasm Interventions: Drug: Fentanyl Sublingual Spray; Drug: Morphine; Other: Physical Performance Testing; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
Conditions: D011471; D064129; D035683; D009360; D014408 Intervention: Diagnostic Test: Periodic ARV7 and miRNA evaluation Sponsor: Azienda Ospedaliero-Universitaria Careggi Recruiting
Condition: Locally Advanced Colon Cancer Intervention: Combination Product: CAPECITABINE AND OXALIPLATIN Sponsor: Universidad de León Recruiting
Condition: Patients With Metastatic Colorectal Cancer Interventions: Drug: Fluoropyrimidine; Drug: Bevacizumab Sponsor: Centre Hospitalier Universitaire Dijon Not yet recruiting
Condition: Breast Cancer Interventions: Drug: Avelumab; Drug: Aspirin; Drug: Lansoprazole Sponsors: The Christie NHS Foundation Trust; University of Manchester Not yet recruiting
Conditions: Nutrition; Physical Activity Interventions: Behavioral: Intervention Physical Activity; Other: Usual Care Sponsors: University of North Carolina, Chapel Hill; University of Texas Completed
Conditions: Neutropenia; Breast Cancer Interventions: Drug: Eflapegrastim; Drug: Docetaxel; Drug: Cyclophosphamide Sponsor: Spectrum Pharmaceuticals, Inc Not yet recruiting
Conditions: Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic; Healthy Intervention: Sponsor: Indiana University Recruiting
Conditions: Neutropenia, Febrile; Leukemia; Pediatric Cancer; Antibiotic Reaction Interventions: Drug: Ceftazidime Injection; Drug: Cefepime Injection Sponsor: Indonesia University Completed
The objective of this study was to evaluate the diagnostic and prognostic value of 18F-FDG PET/CT in patients with cardiac masses. Methods: Whole-body 18F-FDG PET/CT scans of 64 patients with cardiac masses from August 2012 to August 2018 were retrospectively analyzed (34 men, 30 women; mean age, 51.2±17.5 y). Patients were divided into malignant group and benign group. Quantitative analysis of 18F-FDG uptake (SUVmax, SUVmean, Volume and TLG) of the tumors were performed and was compared between the 2 groups. Receiver operator characteristic (ROC) curve was applied to determine the best cut-off value of differentiat...